V.A. Cure is a European MSCA-ITN network aiming to uncover core mechanisms of initiation and maintenance of Vascular Anomalies (VAs) and to leverage this information for establishing novel therapeutic strategies. The network consortium consists of 7 academic laboratories and 2 companies from across Europe, and is supported by 9 partner organisations.
The 14 Early Stage Researchers (ESRs) will be a part of the unique international PhD program, consisting of an individual research project, the network’s training programme, intersectoral secondments and outreach activities. Project goal is to ensure a comprehensive perception of the research and drug/technology development in pharma industry/biotech and academia.
Lymphatic malformation is a debilitating and often incurable disease. Taija Mäkinen’s research group has in an international collaboration studied cellular mechanisms leading to abnormal vessel growth and identified a combination therapy that may allow effective treatment of these malformations. Lymphatic malformations are often congenital vascular anomalies that are characterised by abnormal vessel growth. These malformations
V Dekeuleneer, E Seront, A Van Damme, LM Boon, M Vikkula Until a few years ago, treatment options of vascular malformations were limited to sclerotherapy and/or surgery. Since, it has been demonstrated that the majority of vascular malformations are caused by inherited or somatic mutations in various genes. These discoveries paved the way for the
Finnadvance’s got funded for blood vessel-on-a-chip which could be used to treat rare vascular diseases! Organ- or body-on-chips both speed up the process and improve the safety and patient outcomes. Futuristic, but this can be a reality in 3-5 years! Official press release Finnadvance completes 550k€ seed round led by Voima Ventures and Finnish biotech